Millennium Medical PublishingHighlights in Metastatic Breast Cancer From the European Society for Medical Oncology Virtual Congress 2020

This review and commentary from the ESMO Virtual Congress 2020 features a look at the following trials: ASCENT (sacituzumab govitecan-hziy), IMpassion130 (atezolizumab + nab-paclitaxel), IMpassion131 (first-line paclitaxel +/– atezolizumab), IPATunity130 (ipatasertib + paclitaxel), SEASTAR (rucaparib + sacituzumab govitecan), FLIPPER (fulvestrant/palbociclib), SOLAR-1 (alpelisib + fulvestrant), and FURVA (vandetanib + fulvestrant).

HMP CommunicationsCosibelimab Safe, Clinically Active in Patients With mCSCC

In Study CK-301-101, the primary efficacy endpoint was objective response rate (complete + partial response, by independent central review), which was 47% (n = 15) in 32 metastatic cutaneous squamous cell carcinoma (mCSCC) patients evaluable for response, including three complete responses and 12 partial responses. The results from the study were presented at the ESMO […]

HMP CommunicationsFirst-Line NALIRIFOX Shows Promising Antitumor Activity in Locally Advanced/Metastatic PDAC

In this podcast from the virtual 2020 ESMO World Congress on Gastrointestinal Cancer, Dr. Zev Wainberg discusses emerging data from the phase 1/2 trial of first-line liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin for pancreatic ductal adenocarcinoma (PDAC).